The “Donam Plasma” Association aims to mobilize the resources and skills of the private sector, which will finance, develop and operate the first 10 plasmapheresis centers in Romania, able to collect sufficient quantities of human plasma, from which to manufacture the necessary medicines for Romanian patients.
Thus, the “Donam Plasma” Association will invest the mobilized private funds, to finance the development of some plasmapheresis centers from scratch.
These will be developed in buildings specially designed to meet all the requirements for the authorization of those spaces as plasma collection centers.
They will be equipped with new, modern equipment to ensure the collection, testing, processing, storage and transport of plasma for fractionation.
Staff will be selected and trained to meet the stringent requirements of applicable European law.
The plasma thus collected will be offered to the manufacturers of plasma-derived medicines, who will have to give in return the finished products, respectively the essential medicines necessary for the Romanian patients.
The selection of manufacturers and the negotiation of contracts will be done within a transparent competitive procedure, with constant information of those directly concerned, namely public transfusion centers, medical professional associations, patient rights associations and, last but not least, national health authorities.
The medicines thus obtained will be distributed to hospitals in Romania, in order to cover the needs of Romanian patients.
The “Donam Plasma” Association will further promote the need to modernize Romanian legislation to allow the operation of private plasmapheresis centers, in addition to those operated by non-profit or state organizations. According to the data from Europe, the only countries that manage to collect sufficient quantities of plasma for fractionation are those in which private centers coexist with those of the state. Moreover, these countries (Austria, the Czech Republic, Germany, Hungary) collect at least four times more plasma per 1000 inhabitants than the countries where there are only public centers.
The existence of private plasmapheresis centers will offer Romanians the chance to donate plasma both for Romanian patients, but also for other patients, who, like Romanians, need treatments with medicines made of plasma.
The 10 centers financed, developed and operated by the “Donam Plasma” Association will cover most of the needs of Romanian patients. The private centers will complete the amount of plasma needed to provide the necessary medicines for Romanian patients.
Romania could thus be among the select countries that are no longer in a position to withstand the shocks of the global immunoglobulin market, where discontinuities in the supply of raw materials are becoming more frequent.
Last but not least, the presence of large private companies in the plasma collection sector will sharpen the competition between the manufacturers of plasma-derived medicines, which will lead to a natural decrease in the prices of these medicines for Romanian patients, respectively for the Romanian state that settles them.